JP2025525305A - 半減期延長ドメインを有する融合タンパク質 - Google Patents

半減期延長ドメインを有する融合タンパク質

Info

Publication number
JP2025525305A
JP2025525305A JP2024570660A JP2024570660A JP2025525305A JP 2025525305 A JP2025525305 A JP 2025525305A JP 2024570660 A JP2024570660 A JP 2024570660A JP 2024570660 A JP2024570660 A JP 2024570660A JP 2025525305 A JP2025525305 A JP 2025525305A
Authority
JP
Japan
Prior art keywords
protein
seq
binding
mutein
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024570660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525305A5 (enExample
Inventor
ハウプツ，ウルリッヒ
ボッセ－ドエネッケ，エヴァ
ホフマン，グレゴール
グローザー－ブラウニヒ，マンヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navigo Proteins GmbH
Original Assignee
Navigo Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins GmbH filed Critical Navigo Proteins GmbH
Publication of JP2025525305A publication Critical patent/JP2025525305A/ja
Publication of JP2025525305A5 publication Critical patent/JP2025525305A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024570660A 2022-06-30 2023-06-30 半減期延長ドメインを有する融合タンパク質 Pending JP2025525305A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22182401 2022-06-30
EP22182401.4 2022-06-30
EP22205669 2022-11-04
EP22205669.9 2022-11-04
PCT/EP2023/068109 WO2024003393A1 (en) 2022-06-30 2023-06-30 Fusion proteins with half life extending domains

Publications (2)

Publication Number Publication Date
JP2025525305A true JP2025525305A (ja) 2025-08-05
JP2025525305A5 JP2025525305A5 (enExample) 2026-03-03

Family

ID=87136437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024570660A Pending JP2025525305A (ja) 2022-06-30 2023-06-30 半減期延長ドメインを有する融合タンパク質

Country Status (7)

Country Link
US (1) US20250388696A1 (enExample)
EP (1) EP4547708A1 (enExample)
JP (1) JP2025525305A (enExample)
CN (1) CN119487061A (enExample)
AU (1) AU2023301542B2 (enExample)
CA (1) CA3253055A1 (enExample)
WO (1) WO2024003393A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024401183A1 (en) * 2023-12-12 2026-04-30 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2019091918A1 (en) * 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
CA3139164A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
CA3184995A1 (en) * 2020-07-16 2022-01-20 Navigo Proteins Gmbh Serum stable binding proteins for human her2 for theranostic applications

Also Published As

Publication number Publication date
AU2023301542B2 (en) 2026-06-11
EP4547708A1 (en) 2025-05-07
CA3253055A1 (en) 2024-01-04
AU2023301542A1 (en) 2025-01-02
US20250388696A1 (en) 2025-12-25
WO2024003393A1 (en) 2024-01-04
CN119487061A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
JP7608538B2 (ja) 癌の診断および治療のための新規なｆｏｌｒ１特異的結合タンパク質
EP3706804B1 (en) Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
JP7498971B2 (ja) がん診断及び治療のための新規ｐｓｍａ特異的結合タンパク質
JP2026031936A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）のための特異的結合性分子
US20250388696A1 (en) Fusion proteins with half life extending domains
AU2024401183A1 (en) Novel serum albumin-binding fusion proteins
EP4326749A1 (en) Novel human programmed death ligand 1 (pd-l1) specific binding molecules
EP4161954B1 (en) Serum stable binding proteins for human her2 for theranostic applications
JP2025534423A (ja) プログラム死リガンド１（ｐｄ－ｌ１）に対して高い結合親和性を有する新規タンパク質
CN118317972A (zh) 成纤维细胞活化蛋白（fap）的特异性结合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260220